Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.868
-0.182 (-5.97%)
Dec 3, 2024, 11:58 AM EST - Market open
Lipella Pharmaceuticals Employees
As of December 31, 2023, Lipella Pharmaceuticals had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$69,076
Profits / Employee
-$609,068
Market Cap
3.47M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | 2 | 40.00% |
Dec 31, 2021 | 5 | 0 | - |
Dec 31, 2020 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
China Pharma Holdings | 231 |
Genetic Technologies | 55 |
Catheter Precision | 14 |
Processa Pharmaceuticals | 13 |
Sonoma Pharmaceuticals | 10 |
Chromocell Therapeutics | 8 |
Oragenics | 5 |
Titan Pharmaceuticals | 4 |
LIPO News
- 4 weeks ago - Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 2 months ago - PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - GlobeNewsWire
- 1 year ago - FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - Market Watch
- 1 year ago - Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology - PRNewsWire